DK1771426T3 - Diphenylaminsubstituererede salicylthiazolderivater og beslægtede forbindelser som phosphotyrosinphosphatase 1B (PTP1B) hæmmer til anvendelse som blodsukkersænkende aktive stoffer til behandling af diabetes - Google Patents

Diphenylaminsubstituererede salicylthiazolderivater og beslægtede forbindelser som phosphotyrosinphosphatase 1B (PTP1B) hæmmer til anvendelse som blodsukkersænkende aktive stoffer til behandling af diabetes

Info

Publication number
DK1771426T3
DK1771426T3 DK05756578T DK05756578T DK1771426T3 DK 1771426 T3 DK1771426 T3 DK 1771426T3 DK 05756578 T DK05756578 T DK 05756578T DK 05756578 T DK05756578 T DK 05756578T DK 1771426 T3 DK1771426 T3 DK 1771426T3
Authority
DK
Denmark
Prior art keywords
salicylthiazole
ptp1b
diphenylamine
diabetes
inhibitor
Prior art date
Application number
DK05756578T
Other languages
Danish (da)
English (en)
Inventor
Stefan Petry
Karl-Heinz Baringhaus
Norbert Tennagels
Guenter Mueller
Reinhard Kirsch
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1771426T3 publication Critical patent/DK1771426T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK05756578T 2004-07-17 2005-07-02 Diphenylaminsubstituererede salicylthiazolderivater og beslægtede forbindelser som phosphotyrosinphosphatase 1B (PTP1B) hæmmer til anvendelse som blodsukkersænkende aktive stoffer til behandling af diabetes DK1771426T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004034697A DE102004034697A1 (de) 2004-07-17 2004-07-17 Mit Diphenylamin oder Diphenylaminderivaten substituierte Salicylthiazole, Verfahren zu deren Herstellung und deren Verwendung
PCT/EP2005/007151 WO2006007959A1 (de) 2004-07-17 2005-07-02 Diphenylaminsubstituierte salicylthiazolderivate und verwandte verbindungen als phosphotyrosinphosphatase 1b (ptp1b) hemmer zur verwendung als blutzuckersenkende wirkstoffe zur behandlung von diabetes

Publications (1)

Publication Number Publication Date
DK1771426T3 true DK1771426T3 (da) 2008-05-05

Family

ID=34971604

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05756578T DK1771426T3 (da) 2004-07-17 2005-07-02 Diphenylaminsubstituererede salicylthiazolderivater og beslægtede forbindelser som phosphotyrosinphosphatase 1B (PTP1B) hæmmer til anvendelse som blodsukkersænkende aktive stoffer til behandling af diabetes

Country Status (21)

Country Link
US (1) US7741491B2 (es)
EP (1) EP1771426B1 (es)
JP (1) JP2008506643A (es)
KR (1) KR20070043787A (es)
CN (1) CN100582098C (es)
AR (1) AR049588A1 (es)
AT (1) ATE381551T1 (es)
AU (1) AU2005263418A1 (es)
BR (1) BRPI0513423A (es)
CA (1) CA2574162A1 (es)
DE (2) DE102004034697A1 (es)
DK (1) DK1771426T3 (es)
ES (1) ES2296199T3 (es)
HK (1) HK1104534A1 (es)
IL (1) IL180570A0 (es)
MX (1) MXPA06014443A (es)
PE (1) PE20060554A1 (es)
PT (1) PT1771426E (es)
TW (1) TW200616985A (es)
UY (1) UY29020A1 (es)
WO (1) WO2006007959A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586453B2 (en) * 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
WO2003032916A2 (en) * 2001-10-16 2003-04-24 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
WO2003048140A1 (fr) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
WO2003103648A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 糖尿病治療薬

Also Published As

Publication number Publication date
ES2296199T3 (es) 2008-04-16
US20070191441A1 (en) 2007-08-16
JP2008506643A (ja) 2008-03-06
CN100582098C (zh) 2010-01-20
PE20060554A1 (es) 2006-06-24
CN1989116A (zh) 2007-06-27
UY29020A1 (es) 2006-02-24
WO2006007959A1 (de) 2006-01-26
HK1104534A1 (en) 2008-01-18
ATE381551T1 (de) 2008-01-15
AR049588A1 (es) 2006-08-16
TW200616985A (en) 2006-06-01
CA2574162A1 (en) 2006-01-26
DE102004034697A1 (de) 2006-02-09
EP1771426B1 (de) 2007-12-19
KR20070043787A (ko) 2007-04-25
EP1771426A1 (de) 2007-04-11
US7741491B2 (en) 2010-06-22
BRPI0513423A (pt) 2008-05-06
DE502005002310D1 (de) 2008-01-31
AU2005263418A1 (en) 2006-01-26
IL180570A0 (en) 2007-06-03
PT1771426E (pt) 2008-01-31
MXPA06014443A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
DK1771426T3 (da) Diphenylaminsubstituererede salicylthiazolderivater og beslægtede forbindelser som phosphotyrosinphosphatase 1B (PTP1B) hæmmer til anvendelse som blodsukkersænkende aktive stoffer til behandling af diabetes
FR19C1053I2 (fr) Inhibiteurs de co-transporteur 2 de sodium glucose et procedes d'utilisation de ceux-ci
JP2008506643A5 (ja) 糖尿病の治療用の血糖値低下活性成分として使用するためのホスホチロシン・ホスファターゼ１ｂ(ｐｔｐ１ｂ)阻害剤としてのジフェニルアミン置換サリチルチアゾール誘導体及び関連化合物
DE502005009922D1 (de) Faltbare intravasal einführbare blutpumpe
DK1773964T3 (da) Flerkomponent viskoelastisk overfladeaktivt fluid og anvendelsesfremgangsmåde som fraktureringsfluid
DE602005017840D1 (de) Blutdruckmonitor
DK1830869T3 (da) Fremgangsmåde til behandling eller profylakse
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DK3524261T3 (da) Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
NO20070046L (no) Nytt cykloheksanderivat, prodrug derav og salt derav, og terapeutisk middel inneholdende de samme for diabetes
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DK1756084T3 (da) Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
DK1690550T3 (da) Terapeutisk middel til mesothelioma
DK1734959T3 (da) Forbindelser til behandling af skizofreni og/eller glukoregulerende abnormaliteter
DE502005003383D1 (de) Intrakardiale blutpumpe
DK1617834T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende mælkesyre eller lactat og kalium til behandling af hjerneödem eller hjerneskade
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
DE602005018767D1 (de) Bleichmittel mit carbohydratoxidase
DK1968574T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til behandling af obesitet
DK2125789T3 (da) Pyrimidinylpyrazoler som insekticide og parasiticide aktivstoffer
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.
NO20045554L (no) Fremgangsmate for behandling av diabetes
DE602005000013D1 (de) Doppelschichtkondensator und Elektrolytlösung dafür